MLR, EFPIA, and the AI answer layer.

The compliance questions are arriving faster than the regulatory guidance. Fifty percent of medical chatbot answers are classified as problematic by clinical reviewers — inaccurate, incomplete, or potentially harmful — according to a BMJ Open study of popular AI health tools. In the same environment, the May 2026 PharmaGEO public index finds FDA drug labels ranking as the number-one and number-two cited sources for obesity treatment queries — meaning regulatory documents pharma filed for product approval are being cited to prescribers and patients by AI systems without any brand intervention. This is the compliance landscape pharma legal and MLR teams are navigating: a 50% accuracy failure rate running alongside unsolicited FDA label citation. This article covers the MLR/EFPIA compliance frame for the AI answer layer. For the operational question of how AI systems surface adverse events and safety signals, see our sister piece, AI as a Pharmacovigilance Surface.

The compliance paradox: you do not own the AI answer, but you are responsible for the source

Who owns what

The starting position almost every regulatory team arrives at independently: you do not own the AI answer. When ChatGPT, Gemini, or Perplexity generates a response about your drug, that response is produced by the AI system's own architecture — drawing from its training data and retrieval index. The pharmaceutical company whose brand appears in the answer did not author it, did not approve it, and was not consulted about it. But the sources that fed that answer — the FDA label, the EPAR, the clinical trial publication, the brand website's HTML — are content the company either owns, influenced, or allowed to exist in its current form.

The current consensus among pharma regulatory teams is clear: the AI answer itself is not a pharma promotional piece and is not subject to MLR approval. The responsibility that falls to the pharmaceutical company is responsibility for the owned content it publishes, which may subsequently be indexed and used as a source. That content is fully subject to established regulatory requirements. The practical implication: GEO is fundamentally a content quality and documentation challenge, not a new category of promotional activity requiring a new regulatory framework.

GLP-1 off-label leakage — a real exposure today

The clearest current example of AI-layer compliance exposure is the GLP-1 obesity space. The May 2026 PharmaGEO public index shows that in response to obesity treatment queries, AI engines surface not just Wegovy and Zepbound (the obesity-indicated GLP-1s) but also Ozempic and Mounjaro — both approved for type 2 diabetes, not for obesity. Perplexity's source usage in obesity queries assigns approximately 6% of source appearances to Ozempic and approximately 3% to Mounjaro — non-zero, unprompted, and non-commissioned by the brand teams behind either product.

Each of these unprompted off-label mentions is a compliance exposure in the making. It is a systemic AI behaviour driven by the scientific literature connecting these molecules to weight-loss outcomes — not a brand communications decision. But when a prescriber asks an AI tool about obesity treatment options and receives an answer that includes a type-2-diabetes-only GLP-1 without clinical grading or indication clarity, the brand team of the mentioned product has no visibility into that exchange and no mechanism to correct it in real time. The documented regulatory response is to ensure that the approved-indication content is indexed so authoritatively — through FDA labels, manufacturer prescribing information pages, and society guideline references — that it provides the dominant contextual frame whenever the molecule appears in an AI answer.

The EFPIA framework for GEO content

Non-promotional classification — the operative distinction

EFPIA's Code on the Promotion of Prescription Medicines and its digital communications guidance provide the most relevant European compliance framework for GEO content. The central operative distinction is between promotional and non-promotional content. Non-promotional content — factual, scientific, and educational material that does not carry a promotional intent — is subject to different and generally less restrictive requirements than promotional material.

The content types that perform best in GEO contexts are generally classifiable as non-promotional under EFPIA principles: structured disease-state pages, mechanism of action explainers, clinical evidence summaries, Q&A pages for HCPs. The key test is intent: content created to improve LLM citation rate, but structured as accurate clinical education, should be evaluated under non-promotional criteria. Country-level implementation varies materially — UK ABPI Code, German HWG, and French Charte each carry their own interpretation — so multi-market GEO strategies require country-level legal review before publication.

EMA EPARs as a citation vector pharma already owns

One of the most underutilised compliance assets in GEO strategy is the European Public Assessment Report. The May 2026 PharmaGEO public index identifies EMA EPARs appearing in the top cited sources for atopic dermatitis and psoriasis queries in English-language AI answers. EU regulatory documents are indexed and cited in English-language responses globally — a free citation channel that pharmaceutical companies own through the filing process but rarely optimise for retrieval. The EPAR text — including the summary of product characteristics, efficacy data, and safety section — is hosted on ema.europa.eu and ranks for safety, efficacy, and indication queries across all the major AI retrieval engines. The compliance advantage: EPAR content is already MLR-equivalent (it was reviewed and published by a regulatory authority). Ensuring it is structured for retrieval and cross-linked from brand properties costs nothing in new approvals.

MLR adapted for retrieval-friendly formats

Three format considerations MLR teams have not yet standardised

The standard MLR review process was designed for a defined set of content formats: promotional materials, sales aids, speaker decks, patient leaflets, websites, journal advertisements. It is a document-centric process in which a specific piece of content is reviewed, annotated, approved, and versioned. GEO-optimised content formats do not fundamentally change that process, but they introduce three considerations that most MLR processes have not yet standardised.

First, format specificity: MLR approval of content does not automatically extend to a format change. A claim approved in PDF may need separate review before being published as structured HTML — even if the text is identical. Most legal teams accept that if content is unchanged and the format change is purely structural, reapproval is not required. Confirm this before assuming it applies in your jurisdiction.

Second, query-shaped headings: headings formatted as questions ("What is the recommended starting dose for patients with renal impairment?") may be unfamiliar to MLR reviewers accustomed to evaluating claim statements rather than interrogative headings. Briefing the MLR team on the retrieval rationale prevents unnecessary review cycles.

Third, versioning and the recall gap: if an LLM cites a superseded version of your content, there is no mechanism to recall the citation the way you might withdraw an approved email campaign. The regulatory consensus is that companies should maintain version records and update published content promptly when label changes occur — and are not held responsible for LLM answers that reflect outdated content after the owned source has been corrected. The documentation of that update is what matters.

What an MLR-friendly content audit looks like for the AI layer

The compliance checklist

The safety surface that already exists

A finding from the May 2026 PharmaGEO index that most brand teams have not registered: in pharma therapeutic areas, the AI answer layer is already a safety surface. In obesity queries, Perplexity ranks FDA labels (accessdata.fda.gov) as the number-one and number-two source by use count. Those labels include boxed warnings, contraindications, and REMS where applicable. Brand teams assuming AI answers are marketing copy are operating on a false premise: AI is already delivering mandatory safety and indication information, automatically, because the FDA label is indexed and retrieved. The compliance task is not to introduce safety content to the AI layer — it is already there. The task is to ensure that owned content provides accurate context around that safety content, preventing decontextualised citation of warning language without clinical framing.

The documentation trail you need

Three categories of records that establish regulatory defensibility

In the event of a regulatory inquiry or adverse event investigation that involves an LLM answer about your drug, the documentation trail that demonstrates company diligence should include three categories most GEO programmes have not yet captured.

First, a version record of all owned content published for retrieval: the content version, the MLR approval reference number, the publication date, and the date of any subsequent updates following label changes. This establishes that the authoritative company-owned source was accurate at publication and updated promptly when the label changed — the correct compliance posture in an environment where the company does not control what LLMs index.

Second, records of periodic GEO audits: what LLMs were saying about the brand at regular intervals, scored against the current label. These records demonstrate ongoing monitoring, not passive acceptance of AI-generated brand representation. Critically, they distinguish between company-authored inaccuracies (which create liability) and AI-generated inaccuracies in which the company's owned content was accurate (which does not).

Third, records of correction attempts when material inaccuracies were identified: whether those involved owned-content updates, syndication of corrective material, or engagement with the LLM provider's feedback mechanisms. The documentation of correction effort matters more from a liability standpoint than the success of the correction — because pharma does not control the LLM's response to correction attempts. Building this documentation trail is a straightforward addition to an existing GEO audit programme. The audit records that measure performance also serve as the evidentiary record a regulatory inquiry would require.

Platform-level compliance signal: the 50% problem as a regulatory backdrop

The regulatory consensus is not yet codified in binding guidance, but the direction is clear: companies are expected to monitor, correct owned content, and document. The GEO audit programme that measures brand visibility also generates the evidentiary record that regulatory defensibility requires. The cost of structuring those records correctly is minimal. The cost of having no records when an inquiry arrives is not.

Want a real audit on your brand? Request a sample report or get the full PharmaGEO Playbook.